GlycoMimetics (GLYC) to Release Earnings on Thursday

GlycoMimetics (NASDAQ:GLYCGet Rating) will issue its quarterly earnings data before the market opens on Thursday, April 28th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter.

GlycoMimetics (NASDAQ:GLYCGet Rating) last posted its quarterly earnings data on Thursday, March 3rd. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.02). The firm had revenue of $0.02 million during the quarter. During the same period last year, the business posted ($0.32) earnings per share. On average, analysts expect GlycoMimetics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of NASDAQ:GLYC traded down $0.01 during trading on Tuesday, hitting $0.90. The company had a trading volume of 122,952 shares, compared to its average volume of 211,612. The stock has a market cap of $46.92 million, a price-to-earnings ratio of -0.73 and a beta of 1.82. GlycoMimetics has a one year low of $0.82 and a one year high of $2.83. The company has a fifty day simple moving average of $1.10 and a two-hundred day simple moving average of $1.42.

Separately, StockNews.com began coverage on GlycoMimetics in a report on Saturday. They issued a “hold” rating on the stock. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $5.08.

A number of hedge funds have recently made changes to their positions in GLYC. Geode Capital Management LLC grew its stake in GlycoMimetics by 3.8% during the 3rd quarter. Geode Capital Management LLC now owns 366,301 shares of the biotechnology company’s stock valued at $802,000 after purchasing an additional 13,561 shares during the last quarter. Morgan Stanley grew its stake in GlycoMimetics by 52.9% during the 3rd quarter. Morgan Stanley now owns 67,924 shares of the biotechnology company’s stock valued at $148,000 after purchasing an additional 23,510 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in GlycoMimetics by 46.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 38,533 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 12,158 shares during the last quarter. Finally, Millennium Management LLC grew its stake in GlycoMimetics by 54.4% during the 4th quarter. Millennium Management LLC now owns 691,713 shares of the biotechnology company’s stock valued at $996,000 after purchasing an additional 243,703 shares during the last quarter. Hedge funds and other institutional investors own 57.33% of the company’s stock.

GlycoMimetics Company Profile (Get Rating)

GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML.

Featured Articles

Earnings History for GlycoMimetics (NASDAQ:GLYC)

Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.